Health Economics in HIV Disease: A Review of the European Literature

Youle, M.; Trueman, P.; Simpson, K.
May 1999
PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1
Academic Journal
The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the economic consequences of, differing models of care are poorly documented or understood. Most available economic and clinical data, especially data documenting post-therapy outcomes, are from small, short term studies. This has led to the use of modelling to estimate which determinants can improve the quality and cost effectiveness of HIV care in the future. Although the attempt to provide what is currently perceived to be the standard of care is stretching many healthcare budgets, it is an anachronism that there are few studies of health economics in HIV disease. Most published data relate only to North America, and there remains a paucity of European studies. This paper provides a review of the available data from Europe and attempts to highlight the trends that have taken place to date.


Related Articles

  • Cross Regulation of Sirtuin 1, AMPK, and PPARγ in Conjugated Linoleic Acid Treated Adipocytes. Shan Jiang; Wei Wang; Miner, Jess; Fromm, Michael // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor γ (PPARγ) generally opposing these reductions....

  • Universal Access to HIV Treatment versus Universal 'Test and Treat': Transmission, Drug Resistance & Treatment Costs. Wagner, Bradley G.; Blower, Sally; Cameron, D. William // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ∼1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal 'test and treat' (T&T) strategy to try to...

  • Initiating HAART earlier a prudent move in HIV infections.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p7 

    Presents information on a study which focused on the significance of the early initiation of highly active antiretroviral therapy among patients with HIV infections. Cost effectiveness of the strategy; Association of the strategy with quality-adjusted survival; Results of sensitivity analysis.

  • A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study. Cooper, Curtis; la Porte, Charles; Tossonian, Harout; Sampalis, John; Ackad, Nabil; Conway, Brian // HIV Clinical Trials;Jul/Aug2012, Vol. 13 Issue 4, p179 

    Background: A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. Methods: A prospective, open-label pilot simplification study...

  • No Association of Cryptococcal Antigenemia with Poor Outcomes among Antiretroviral Therapy-Experienced HIV-Infected Patients in Addis Ababa, Ethiopia. Smitson, Christopher C.; Tenna, Admasu; Tsegaye, Mulugeta; Alemu, Abere S.; Fekade, Daniel; Aseffa, Abraham; Blumberg, Henry M.; Kempker, Russell R. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Introduction: There are limited data on clinical outcomes of ART-experienced patients with cryptococcal antigenemia. We assessed clinical outcomes of a predominantly asymptomatic, ART-experienced cohort of HIV+ patients previously found to have a high (8.4%) prevalence of cryptococcal...

  • superinfection a changing picture. Duffin, Ross // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p9 

    Discusses the impact of superinfection on an individual's HIV disease progression. Overview of several HIV superinfection cases in Australia; Frequency of the occurrence of superinfection; Recommended approach to prevent HIV superinfection.

  • One thousand words.  // CMAJ: Canadian Medical Association Journal;3/18/2003, Vol. 168 Issue 6, p748 

    Reports that only five percent of people with HIV/AIDS have access to life-prolonging medication. Efforts of the organization Doctors without Borders to gather financial support for struggling economies; Consideration of commercial rights such as patent protection.

  • Accrued HIV evidence turns treatment dogma on its head. Check, Erika // Nature;8/21/2003, Vol. 424 Issue 6951, p866 

    Focuses on the possible health risk posed by HIV drugs in patients. Inefficacy of drugs in subduing virus in HIV positive patients; Comments of various researchers on HIV therapy; Thoughts over the distribution of drugs among various developing countries.

  • A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Hahn, K.; Arendt, G.; Braun, J. S.; von Giesen, H.-J.; Husstedt, I. W.; Maschke, M.; Straube, E.; Schielke, E. // Journal of Neurology;Oct2004, Vol. 251 Issue 10, p1260 

    Background Painful HIV-associated sensory neuropathies (HIV-SN) are a common complication of HIV infection. The pathogenesis is unknown and the treatment very limited. Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics